NCNA
vs
S&P 500
NCNA
S&P 500
Over the past 12 months, NCNA has underperformed S&P 500, delivering a return of -99% compared to the S&P 500's +14% growth.
Stocks Performance
NCNA vs S&P 500
Performance Gap
NCNA vs S&P 500
Performance By Year
NCNA vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
NuCana PLC
Glance View
NuCana Plc engages in the development of technology platform for the treatment of patients with cancer. The firm is focused on developing treatments for cancer patients using its ProTide technology. ProTide are designed to overcome cancer resistance mechanism and generate anti-cancer metabolites in cancer cells. The firm's pipeline includes Acelari, NUC-3373, and NUC-7738. Its ProTide candidates Acelari and NUC-3373 are chemical entities derived from the nucleotide analog and 5- fluorouracil, which are used as chemotherapy agents for the treatment of cancer. Acelari is in a Phase III study for patients with biliary tract cancer. NUC-3373 is in Phase I study for the treatment of a range of patients with solid tumors and a Phase I b study for patient with metastatic colorectal cancer. Its third ProTide candidate, NUC-7738, is a nucleotide analog (3’-deoxyadenosine) and is in Phase I study for patients with solid tumors.
